Drug Development in Schizophrenia: Summary and Table

@article{2014DrugDI,
  title={Drug Development in Schizophrenia: Summary and Table},
  author={},
  journal={Pharmaceutical Medicine},
  year={2014},
  volume={28},
  pages={265-271}
}
  • Published 2014
  • Psychology, Medicine
  • Pharmaceutical Medicine
Older conventional antipsychotics (APs) have given way to newer atypical APs, but many patients remain refrac-tory to treatment. Genetic and biomarkers studies have revealed that schizophrenia is a very heterogeneous disease. Current unmet needs include lack of adequate effi-cacy—incomplete suppression of psychosis prevents brain repair leading to permanent cognitive deficits—novel agents with lower neurotoxicity and vascular risk, and a need for earlier diagnosis of the negative symptoms…